PCI Biotech - Fundamentale forhold (PCIB)

[Sponplate]

Endringer under “Eligibility”:

[Jubel]

For noen resultater​:bomb:

12:20 PHOTOCHEMICAL INTERNALISATION (PCI) – ENHANCED AND SITE-DIRECTED OLIGONUCLEOTIDE AND MRNA DELIVERY BY LIGHT-INDUCED ENDOSOMAL RELEASE

Anders Hogset, Chief Scientific Officer, PCI Biotech AS
View Bio

• PCI can strongly enhance both vehicle-mediated- and naked RNA delivery
• In vivo, PCI enhances the delivery of naked mRNA up to 50 times as compared to mRNA alone
• For intratumoural mRNA delivery, PCI with naked mRNA compares favourably to delivery by LNPs
• PCI site-directs delivery by illumination

PCI Biotech - Småprat 4 (PCIB)

12:20 PHOTOCHEMICAL INTERNALISATION (PCI) – ENHANCED AND SITE-DIRECTED OLIGONUCLEOTIDE AND MRNA DELIVERY BY LIGHT-INDUCED ENDOSOMAL RELEASE [Anders Hogset] Anders Hogset, Chief Scientific Officer, PCI Biotech AS View Bio PCI can strongly enhance both vehicle-mediated- and naked RNA delivery In vivo, PCI enhances the delivery of naked mRNA up to 50 times as compared to mRNA alone For intratumoural mRNA delivery, PCI with naked mRNA compares favourably to delivery by LNPs PCI site-directs de…

PCI Biotech - Småprat 4 (PCIB)

Ett eller annet litt utenom det vanlige må jo den posten på programmet bety? Og i så fall er det i alle fall ikke negativt.

40 minutter og et dypdykk. Spennende !!
Ukjent for meg med disse detaljer. Mulig det kommer ytterligere data på presentasjon og kommentarer. AZ deltar også på konferansen sammen med Moderna, Roche og alt som kan krype å gå innen mRNA og CRISPR ser det ut til!

RNA Therapeutics

[the1nonly]

Dette er vel ikke noe nytt. PCIB har formidlet dette budskapet lenge nå.

[Jubel]

@the1nonly. Jeg har aldri lest disse egenskapene og data på Nac! Har du link på hvor dette er kjent fra før. Leste gjennom siste Q presentasjon, intet der.

PCI Biotech - Småprat 4 (PCIB)

Kanskje de benytter anledningen til å takke for sist ved å sette AZ/Moderna og BNTX helt i skyggen hva gjelder resultater!

[Stupet]

@Jubel

For intratumoural mRNA delivery, PCI with naked mRNA compares favourably to delivery by LNPs

Kan det komme noe topplinje data fra AZ samarbeide her for å underbygge dette?

[polygon]

Jaggu. Da var PCIB bare litt trege med å melde fra til arrangørene om hva de ville snakke om da.

Men fortsatt fint at de er på denne konferansen og sprer budskapet da. Legg merke til at poengterer at de bedrer levering med vehicle også. At det altså ikke nødvendigvis er slik at LNP er en konkurrent.

[ufo]

Kanskje de burde børseldt også?
Om ikke annet enn for at flere får kjennskap til selskapet og teknologien.

[busk1]

@Jubel

Har du link på hvor dette er kjent fra før.

F.eks. lysark 21 i presentasjonen på Jefferies-konferansen i november 2019

[Jubel]

Takk busk1. Utrolig gode resultater!!! Det er da også noen nye moment og data som ikke tidligere var kjent. Uthevet under:

Dette bør kunne bli butikk?!

• PCI can strongly enhance both vehicle-mediated- and naked RNA delivery
• In vivo, PCI enhances the delivery of naked mRNA up to 50 times as compared to mRNA alone
• For intratumoural mRNA delivery, PCI with naked mRNA compares favourably to delivery by LNPs
• PCI site-directs delivery by illumination

Som Polygon nevner over som er viktig og nytt:» Men fortsatt fint at de er på denne konferansen og sprer budskapet da. Legg merke til at poengterer at de bedrer levering med vehicle også. At det altså ikke nødvendigvis er slik at LNP er en konkurrent.»

Og som Investor påpeker: «Kanskje de benytter anledningen til å takke for sist ved å sette AZ/Moderna og BNTX helt i skyggen hva gjelder resultater!»

[TekBot]

PCI Biotech to present at RNA Therapeutics Virtual Conference

Oslo (Norway), 22 January 2021 - PCI Biotech (OSE: PCIB), a clinical-stage
biopharma company developing innovative therapeutics that address significant
unmet medical needs in cancer today announced that it will present at the
…

Vis børsmeldingen

12(th) Annual RNA Therapeutics Virtual Conference, a UK based online event
taking place February 10-11, 2021. The 2021 conference is set to explore the
latest developments in RNA delivery agents and RNA-based therapeutics with the
latest case studies on advanced mRNA technologies, oligonucleotide delivery,
therapeutic applications and future trends and innovations. PCI Biotech is also
a sponsor of the event.

On Wednesday, February 10, 2021 at 13:10pm (CET), Dr. Anders Høgset, CSO, will
present an overview of PCI Biotech’s proprietary platform technology, focusing
on the delivery of RNA molecules, including the most recent data on the use of
the fimaNAc delivery technology in the exciting field of RNA based therapies.
The presentation slides will be made available through a separate press release
around the timing of the presentation and the full presentation will be made
available on PCI Biotech’s website (www.pcibiotech.com) under “Scientific
publications & presentations” after the event.

Contact information:
Per Walday, CEO
pw@pcibiotech.no (mailto:pw@pcibiotech.no)
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Kilde

[magga]

" including the most recent data on the use of
the fimaNAc delivery technology in the exciting field of RNA based therapies."

skulle vel tro dette gjelder PCIB/AZ samarbeidet?

[Stupet]

‘‘The presentation slides will be made available through a separate press release around the timing of the presentation …’’
Ja, skal de presentere noe børssensitivt?

[Investor]

@magga

skulle vel tro dette gjelder PCIB/AZ samarbeidet?

Definitivt. Da får vi de vite mer om de nye indikasjonene også utenfor kreft.

[Jubel]

Pcib fimaVacc (PCIB)

Jeg ved ikke hvem som fandt denne men den er ganske interessant i forhold til Pcib. I korte trækk viser det at der kan være problemer med noe av innholdet i de lipider som leverer covid 19 vaccine fra Moderna og Pfizer/Biontec - Specifikt polyethylene glycol (PEG), som er en del av lipidet og øker stabiliteten og livs lengden til lipidet. Det man er redd for er at immunforsvaret skal bli immun overfor PEG (danne antistoffer mot), som vil bety at man ikke kan bruke dette lengere. Studier har…

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @lenny (1555 likes)

@lenny

Jeg vet mange er lei AZ-PCIB snakk, vil fokusere videre, og legge dette bak seg. Jeg lover at dette er mitt siste innlegg om AZ, men jeg klarte ikke å holde meg borte fra å spekulere en siste gang, slik at det er sagt. Der er nemlig en logisk og vesentlig brist i forklaringene som er gitt på Q, podcaster og børsmeldingen. Jeg har hørt gjennom flere ganger, og det er noe som ikke stemmer.

2. @Jubel (1173 likes)

@Jubel

Photochemical internalization enhanced vaccination is safe, and gives promising cellular immune responses to an HPV peptide-based vaccine in a phase I clinical study in healthy volunteers

3. @bamse (908 likes)

@bamse

Jeg tror Professor Sjoerd van der Burg kan vise seg å bli en nøkkelperson for PCIB.

Resten av topp 10:

4. @Investor (773 likes)

5. @Durable (556 likes)

6. @solo (374 likes)

7. @Sorlendingen (362 likes)

8. @ufo (359 likes)

9. @polygon (359 likes)

10. @abacus (342 likes)

Gratulerer!

[TekBot]

PCI Biotech - release of the RNA Therapeutics Virtual Conference presentation

Oslo (Norway), 10 February 2021 - PCI Biotech (OSE: PCIB), a clinical-stage
biopharma company developing innovative therapeutics that address significant
unmet medical needs in cancer today released the fimaNAc focused presentation
…

Vis børsmeldingen

for the 12(th) Annual RNA Therapeutics Virtual Conference, a UK based online
event taking place February 10-11, 2021. The 2021 conference is set to explore
the latest developments in RNA delivery agents and RNA-based therapeutics with
the latest case studies on advanced mRNA technologies, oligonucleotide delivery,
therapeutic applications and future trends and innovations. PCI Biotech is also
a sponsor of the event.

Today, Wednesday February 10 2021, at 13:10pm (CET) Dr. Anders Høgset, CSO, will
present an overview of PCI Biotech’s proprietary platform technology, focusing
on the delivery of RNA molecules, including the most recent data on the use of
the fimaNAc delivery technology in the exciting field of RNA based therapies.

Per Walday, CEO of PCI Biotech, comments: Encouraging collaborative preclinical
results have recently been achieved with the fimaNAc technology and we are very
pleased to be able to share these data now. The rapid development progress of
mRNA-based vaccines against Covid-19 has generated much attention to the
potential of nucleic acid therapeutics generally, and mRNA particularly. The
results with fimaNAc suggests that this technology provides an appealing
intracellular delivery solution for certain applications within this class of
therapeutics.

An online recording of the full presentation held by Dr Høgset will be made
available on PCI Biotech’s website (www.pcibiotech.com) under “Scientific
publications & presentations” after the event.

Contact information:
Per Walday, CEO
pw@pcibiotech.no (mailto:pw@pcibiotech.no)
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Kilde

[theroger]

Per Walday, CEO of PCI Biotech, comments: Encouraging collaborative preclinical results have recently been achieved with the fima NAc technology and we are very pleased to be able to share these data now. The rapid development progress of mRNA-based vaccines against Covid-19 has generated much attention to the potential of nucleic acid therapeutics generally, and mRNA particularly. The results with fima NAc suggests that this technology provides an appealing intracellular delivery solution for certain applications within this class of therapeutics.

[Hod]

INTRATUMOURAL DELIVERY WITH fimaNAC IS CONVINCINGLY SUPERIOR TO LNPS

For en konferanse å komme med ett slikt utsagn!

[Investor]

fimaNAC with 3 µg mRNA increased luciferase activity about 35 times as compared to the LNPs

[danron10]

“In vivo, fimaNAc - mediated local enhancement of siRNA effect has been demonstrated in tumours and in SKIN”

Boom!